SNMMI, Zionexa call out CMS for reimbursement error

By AuntMinnie.com staff writers

February 8, 2021 -- The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is teaming up with Zionexa to urge the U.S. Centers for Medicare and Medicaid Services (CMS) to properly reimburse Cerianna, a radiolabeled F-18 fluoroestradiol radiotracer indicated for use with PET.

The imaging agent is used to detect estrogen receptor-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. At the moment, the current rate of reimbursement is $0.752 per millicurie for Medicare patients instead of $608.33 per millicurie.

CMS said any corrections would be retroactive to January 1, but the correction isn't likely to happen until March for April or July implementation, according to the SNMMI.


Copyright © 2021 AuntMinnie.com
 

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: